Nature:癌症免疫疗法新发现:阻断一种蛋白,让肿瘤明显缩小

2018-06-29 小通 生物通

免疫疗法在许多癌症类型中显示出很大的希望,但迄今为止,它们在前列腺癌中的作用仅限于一小部分男性。这项新研究发现了一种全新的方法来修改免疫系统以对抗前列腺癌。

免疫疗法在许多癌症类型中显示出很大的希望,但迄今为止,它们在前列腺癌中的作用仅限于一小部分男性。这项新研究发现了一种全新的方法来修改免疫系统以对抗前列腺癌。

一组研究人员发现,针对晚期前列腺癌患者,利用一种新的免疫疗法可以重新激活患者对激素治疗的反应,这在小鼠和人类前列腺癌细胞实验中得到了证实。研究人员认为,这与既有的治疗方法相结合可以改善前列腺癌的预后。

这一研究成果公布在6月27日的Nature杂志上。

激素疗法(Hormone therapy)是前列腺癌治疗的中流砥柱,但是经过治疗,肿瘤细胞会发展出耐药性,导致疾病难以进一步治疗。

这项新研究发现,阻断由一类免疫细胞:称为髓样抑制细胞(Myeloid-derived suppressor cells,MDSCs)产生的蛋白,能恢复肿瘤对激素治疗的敏感性。这种蛋白即IL-23,其实已经被用于了自身免疫性疾病,如牛皮癣等的治疗中。

阻断IL-23,肿瘤缩小

伦敦癌症研究所的与瑞士癌症研究所的研究人员一道,采集了前列腺癌患者的肿瘤和血液样本,希望能了解髓样抑制细胞在前列腺癌中的作用。

他们发现,比较于依然对激素治疗有反应的患者,患有耐药性前列腺癌的患者的血液和肿瘤样本中,这种抑制细胞和IL-23含量水平更高。

并且当研究人员分析不再产生IL-23的前列腺癌的小鼠时,他们发现小鼠的肿瘤显着萎缩,癌细胞生长得更慢。前列腺肿瘤对激素治疗耐药性出现也需要更长的时间,并且小鼠存活的时间更长。

阻断IL-23和阻止抑制细胞进入肿瘤,能帮助改善对激素治疗的反应,由此研究人员相信他们找到了驱动前列腺癌激素治疗抗性的关键机制。

他们指出,IL-23允许前列腺癌细胞避开雄激素激素的需求来促进其生长。

激素疗法与免疫疗法

癌症免疫疗法通过重新激活免疫系统,识别和杀死癌细胞发挥作用,在前列腺癌治疗中显示出一定的前景,但只有一部分男性对此反应良好。

而对于已经扩散到腺体以外的前列腺癌的治疗,经常会改变男性的激素平衡。由于睾酮具有促进前列腺生长的作用,所以激素疗法的目的就是要防止癌细胞和正常前列腺组织接受男性激素的刺激。但激素疗法只对前列腺癌起一个缓解作用,不能进行根治。

伦敦癌症研究学会Johann de Bono教授表示,“激素疗法在男性前列腺癌中效果很好,但是当癌症发展成为对治疗产生抵抗时,其它选择会大大减少。”

“我们的研究发现激素信号与免疫系统之间存在重要的相互作用,我们相信我们可以利用这一点来逆转前列腺癌中的激素耐药性,并增强广泛使用的前列腺癌药物,如enzalutamide的疗效。”

“我们希望能开展临床试验,研究如何将这种新型免疫疗法与现有的激素疗法结合起来,改善晚期前列腺癌患者的治疗。”

另外一位作者,IOR癌症研究所的Andrea Alimonti教授也解释到,“当我们发现产生IL23的MDSCs是激素治疗产生抗性的主要前列腺癌免疫细胞亚型时,我们立即意识到这些细胞可能是导致治疗抗性出现的原因之一。”

“这项研究描述了一种新的作用机制,通过这种机制,肿瘤免疫应答会支持前列腺癌的生长,这为将来转移性前列腺癌患者的新型治疗应用开辟了道路。”

免疫疗法在许多癌症类型中显示出很大的希望,但迄今为止,它们在前列腺癌中的作用仅限于一小部分男性。这项新研究发现了一种全新的方法来修改免疫系统以对抗前列腺癌。

激素疗法与这种新型免疫疗法的结合可能是一种令人兴奋的治疗晚期前列腺癌的新途径。

原始出处:Arianna Calcinotto, Clarissa Spataro, Elena Zagato, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature (2018) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921225, encodeId=9b031921225dd, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Sep 16 15:32:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710148, encodeId=22d31e101489d, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Jan 05 23:32:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883129, encodeId=637018831292a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 25 00:32:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327918, encodeId=94c732e918d8, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Jun 29 08:38:23 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327911, encodeId=97c532e9111e, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jun 29 08:10:40 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921225, encodeId=9b031921225dd, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Sep 16 15:32:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710148, encodeId=22d31e101489d, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Jan 05 23:32:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883129, encodeId=637018831292a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 25 00:32:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327918, encodeId=94c732e918d8, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Jun 29 08:38:23 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327911, encodeId=97c532e9111e, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jun 29 08:10:40 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921225, encodeId=9b031921225dd, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Sep 16 15:32:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710148, encodeId=22d31e101489d, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Jan 05 23:32:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883129, encodeId=637018831292a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 25 00:32:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327918, encodeId=94c732e918d8, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Jun 29 08:38:23 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327911, encodeId=97c532e9111e, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jun 29 08:10:40 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2019-04-25 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1921225, encodeId=9b031921225dd, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Sep 16 15:32:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710148, encodeId=22d31e101489d, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Jan 05 23:32:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883129, encodeId=637018831292a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 25 00:32:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327918, encodeId=94c732e918d8, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Jun 29 08:38:23 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327911, encodeId=97c532e9111e, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jun 29 08:10:40 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-29 kafei

    学习学习谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1921225, encodeId=9b031921225dd, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Sun Sep 16 15:32:00 CST 2018, time=2018-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710148, encodeId=22d31e101489d, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Sat Jan 05 23:32:00 CST 2019, time=2019-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883129, encodeId=637018831292a, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Apr 25 00:32:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327918, encodeId=94c732e918d8, content=学习学习谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Fri Jun 29 08:38:23 CST 2018, time=2018-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=327911, encodeId=97c532e9111e, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Fri Jun 29 08:10:40 CST 2018, time=2018-06-29, status=1, ipAttribution=)]
    2018-06-29 龙胆草

    学习谢谢分享

    0

相关资讯

里程碑:免疫药物引领肺癌治疗划时代标杆

医学专家们认为这些最新研究成果将改变医生治疗肺癌的方式:这类肺癌病人应该尽早接受免疫治疗。

Allergy:花粉季节新的EAACI定义能够反应草和桦树花粉诱导的过敏性鼻炎症状负荷

过敏原免疫疗法(AIT)在过敏性鼻炎中的使用和它的临床试验效果依赖于花粉过敏原接触的时期的有效判断。最近,有研究人员评估了德国花粉数据资料,从而来调查对花粉季节和花粉峰值开始和结束时间的新的定义。研究人员的目的是依据现实生活数据来阐释这些定义反应草和桦树花粉诱导的过敏性鼻炎症状负荷的能力。研究人员利用来自德国柏林和勃兰登堡4个花粉检测地点的3年(2014-2016)的数据来进行季节定义、桦树和草花

2018 SITC共识声明:皮肤黑色素瘤的免疫治疗(更新版)

2018年5月,肿瘤免疫治疗学会(SITC)更新发布了皮肤黑色素瘤的免疫治疗共识,该共识声明是对2013版共识的更新,癌症免疫治疗已被确定为晚期以及转移性黑素瘤患者的标准治疗方法。临床试验的治疗结果已经令11种新药获批。本文主要针对黑色素瘤患者选择免疫治疗提供指导建议。

全球权威机构发布10条防癌建议、免疫疗法治愈乳腺癌……|BioWeek一周事

本周,全球权威机构重磅发布10条“防癌建议”;从生命只剩3个月到告别癌症,免疫疗法治愈乳腺癌;“三亲婴儿”再亮绿灯,新加坡有望“合法化”线粒体替代疗法;Nature子刊“惊人发现”:CRISPR可能增加癌症风险;PNAS惊人发现:人类智商在缓慢下跌……更多资讯,请跟随小编一起回顾吧。

Nat Med:免疫疗法有望治疗晚期癌症

一项新研究称,一位患者的免疫系统经过调整后完全消除了乳腺癌细胞,为所有常规治疗无效的晚期癌症提供了一种可能的治疗方法。这是T细胞免疫疗法首次成功应用于晚期乳腺癌。相关成果6月4日在线发表于《自然—医学》。

Brit J Cancer:转移性肾细胞癌免疫组合治疗后VEGFR TKI治疗效果研究

研究人员发现,那些接受了一线基于免疫的组合疗法(IC)包括免疫检查点抑制剂(CPI)以及接受了随后的系统性治疗的患者的治疗结果到目前仍旧未知。最近,有研究人员对那些患有透明细胞肾细胞癌(mRCC)的连续性病人进行了回顾性分析。研究总共包括了33名患者【平均年龄57岁(37-77),85%为男性,73% ECOG 0】。对那些可以评价的患者(N=28),第一次后续治疗最好的响应为29%具有响应,54